Gene therapy targeting RGCs to prevent BAX activation in a glaucoma model has not yet been performed, making this a clinically relevant approach that can also be tested in wild-type mice without the developmental defects associated with Bax deletion. The gene discussed is BAX; the disease is glaucoma.